Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases

Clinical Cancer Research

Volumn 21, Issue 14, 2015, Pages 3149-3159

  Katz, Steven C ^a,b   Burga, Rachel A ^a,b   McCormack, Elise ^a,b   Wang, Li Juan ^a   Mooring, Wesley ^a   Point, Gary R ^a,b   Khare, Pranay D ^a   Thorn, Mitchell ^a,b   Ma, Qiangzhong ^a,b   Stainken, Brian F ^a,b   Assanah, Earle O ^a,b   Davies, Robin ^a   Espat, N Joseph ^a,b   Junghans, Richard P ^a,b  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN RECEPTOR;

ADENOCARCINOMA; ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CAUSE OF DEATH; CELL THERAPY; COLON ADENOCARCINOMA; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; HEPATIC ARTERY; HUMAN; INFUSION; LIVER BIOPSY; LIVER FIBROSIS; LIVER METASTASIS; LIVER NECROSIS; MALE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; SYSTEMIC THERAPY; T LYMPHOCYTE; TUMOR VOLUME; VATER PAPILLA CARCINOMA; AGED; CLINICAL TRIAL; GASTROINTESTINAL NEOPLASMS; IMMUNOTHERAPY; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROCEDURES; REGIONAL PERFUSION; SECONDARY; TRANSPLANTATION;

ADENOCARCINOMA; AGED; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84942910678     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1421     Document Type: Article

References (47)

1. Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC, et al. Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol 2013;20:946-55.
2. Katz SC, Donkor C, Glasgow K, Pillarisetty VG, Gonen M, Espat NJ, et al. T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases. HPB (Oxford) 2010;12:674-83.
3. Katz SC, Pillarisetty V, Bamboat ZM, Shia J, Hedvat C, Gonen M, et al. T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol 2009;16:2524-30.
4. Wagner P, Koch M, Nummer D, Palm S, Galindo L, Autenrieth D, et al. Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer. Ann Surg Oncol 2008;15:2310-7.
5. Turcotte S, Katz SC, Shia J, Jarnagin WR, Kingham TP, Allen PJ, et al. Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases. Cancer Immunol Res 2014;2:530-7.
6. Cantor HM, Dumont AE. Hepatic suppression of sensitization to antigen absorbed into the portal system. Nature 1967;215:744-5.
7. Katz SC, Pillarisetty VG, Bleier JI, Kingham TP, Chaudhry UI, Shah AB, et al. Conventional liver CD4 T cells are functionally distinct and suppressed by environmental factors. Hepatology 2005;42:293-300.
8. Katz SC, Pillarisetty VG, Bleier JI, Shah AB, De Matteo RP. Liver sinusoidal endothelial cells are insufficient to activate T cells. J Immunol 2004;173:230-5.
9. Katz SC, Ryan K, Ahmed N, Plitas G, Chaudhry UI, Kingham TP, et al. Obstructive jaundice expands intrahepatic regulatory T cells, which impair liver T lymphocyte function but modulate liver cholestasis and fibrosis. J Immunol 2011;187:1150-6.
10. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18.
11. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33.
12. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009;21:215-23.
13. Ma Q, Gonzalo-Daganzo R, Junghans RP. Genetically engineered T cells as adoptive immunotherapy of cancer. In: Giaccone G, Schilsky R, Sondel P, editors. Cancer Chemotherapy & Biological Response Modifiers: Elsevier Science; Philadelphia, PA, 2002. p. 319-45.
14. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol 2011;29:550-7.
15. Ma Q, Gomes EM, Lo AS, Junghans RP. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy. Prostate 2014;74:286-96.
16. Blumenthal RD, Leon E, Hansen HJ, Goldenberg DM. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer 2007;7:2.
17. Midiri G, Amanti C, Benedetti M, Campisi C, Santeusanio G, Castagna G, et al. CEA tissue staining in colorectal cancer patients. A way to improve the usefulness of serial serum CEA evaluation. Cancer 1985;55:2624-9.
18. Emtage PC, Lo AS, Gomes EM, Liu DL, Gonzalo-Daganzo RM, Junghans RP. Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin Cancer Res 2008;14:8112-22.
19. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011;19:620-6.
20. Kemeny NE, Melendez FD, Capanu M, Paty PB, Fong Y, Schwartz LH, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009;27:3465-71.
21. Keilholz U, Scheibenbogen C, Brado M, Georgi P, Maclachlan D, Brado B, et al. Regional adoptive immunotherapy with interleukin-2 and lymphokineactivated killer (LAK) cells for liver metastases. Eur J Cancer 1994;30A:103-5.
22. Kobari M, Egawa S, Shibuya K, Sunamura M, Saitoh K, Matsuno S. Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer. Br J Surg 2000;87:43-8.
23. Komatsu T, Yamauchi K, Furukawa T, Obata H. Transcatheter arterial injection of autologous lymphokine-activated killer (LAK) cells into patients with liver cancers. J Clin Immunol 1990;10:167-74.
24. Matsuhashi N, Moriyama T, Nakamura I, Ishikawa T, Ohnishi S, Nakagama H, et al. Adoptive immunotherapy of primary and metastatic liver cancer via hepatic artery catheter. Eur J Cancer 1990;26:1106-7.
25. Melichar B, Touskova M, Blaha M, Vesely P, Dvorak J, Krajina A, et al. Hepatic arterial administration of activated leukocytes in patients with liver metastases. Cancer Biother Radiopharm 2002;17:545-52.
26. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20.
27. Beaudoin EL, Bais AJ, Junghans RP. Sorting vector producer cells for high transgene expression increases retroviral titer. J Virol Methods 2008;148:253-9.
28. Quintas-Cardama A, Yeh RK, Hollyman D, Stefanski J, Taylor C, Nikhamin Y, et al. Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application. Hum Gene Ther 2007;18:1253-60.
29. Karimi MA, Lee E, Bachmann MH, Salicioni AM, Behrens EM, Kambayashi T, et al. Measuring cytotoxicity by bioluminescence imaging outperforms the standard chromium-51 release assay. PLoS ONE 2014;9:e89357.
30. Junghans RP, Manning W, Safar M, Quist W. Biventricular cardiac thrombosis during interleukin-2 infusion. N Engl J Med 2001;344:859-60.
31. Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 2007;25:5649-54.
32. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802-7.
33. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17:968-75.
34. Lo AS, Ma Q, Liu DL, Junghans RP. Anti-GD3 chimeric sFv-CD28/Tcell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin Cancer Res 2010;16:2769-80.
35. Bramswig KH, Poettler M, Unseld M, Wrba F, Uhrin P, Zimmermann W, et al. Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis. Cancer Res 2013;73:6584-96.
36. Takayama T, Makuuchi M, Sekine T, Terui S, Shiraiwa H, Kosuge T, et al. Distribution and therapeutic effect of intraarterially transferred tumorinfiltrating lymphocytes in hepatic malignancies. A preliminary report. Cancer 1991;68:2391-6.
37. Kooreman NG, Ransohoff JD, Wu JC. Tracking gene and cell fate for therapeutic gain. Nat Mater 2014;13:106-9.
38. Saied A, Licata L, Burga RA, Thorn M, McCormack E, Stainken BF, et al. Neutrophil: lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases. Cancer Gene Ther 2014;21:457-62.
39. Hansen HJ, Goldenberg DM, Newman ES, Grebenau R, Sharkey RM. Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen. Cancer 1993;71:3478-85.
40. Scheinberg DB, Mulford DA, Jurcic JG, Sgouros G, Junghans RP. Antibodybased therapies for cancer. In: Chabner BA, Longo DL, editors. Cancer Chemotherapy and Biotherapy. 4th ed; Lippincott, Williams, and Wilkins; Philadelphia, PA, 2006. p. 666-98.
41. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233-9.
42. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 1985;135:2865-75.
43. Gershwin M. E. VJM, Manns M. P. Liver Immunology. 1st ed. Philadelphia: Hanley & Belfus, Inc.; 2003.
44. Pillarisetty VG, Shah AB, Miller G, Bleier JI, De Matteo RP. Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition. J Immunol 2004;172:1009-17.
45. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
46. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
47. Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006;107:1325-31.